Clinical trials: Carcinoma, Non-Small-Cell Lung Cancer
Non-Small Cell Lung Cancer
Preoperative Structured Exercise Programme on Patients With Non-Small Cell Lung Cancer
INTRODUCTION: Lung cancer is among the leading cancers, and surgery has a major role in treatment. Patients diagnosed with Non-Small Cell Lung Cancer (NSCLC) who are eligible for surgical treatment have a high risk of…
- Trial name
- READY-LUNG (NCT07401056)
- Testing
- Prehabilitation (Structured Preoperative Exercise Programme)
- Where
- Turkey (Türkiye)
- Volunteers
- 62 people
- Sponsor
- Hacettepe University
Carcinoma, Non-Small-Cell Lung
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
The goal of this study is to learn if people who receive intismeran autogene and pembrolizumab after surgery are cancer-free longer than people who receive placebo and pembrolizumab.
- Trial name
- NCT06623422
- Testing
- Pembrolizumab, Cisplatin, Carboplatin
- Where
- 245 sites in United States, Argentina and 29 more
- Volunteers
- 680 people
- Sponsor
- Merck Sharp & Dohme LLC
Ovarian Cancer, Colorectal Cancer
EMD 273066 in Patients With Recurrent EpCAM Positive Ovarian, Prostate, Colorectal or Non-small Cell Lung Cancers When First Given Cyclophosphamide
This study is looking at the safety and tolerability of the experimental biological drug EMD 273066 when given with low dose cyclophosphamide to patients with recurring EpCAM positive ovarian, prostate, colorectal or non-small…
- Conditions
- Ovarian Cancer, Colorectal Cancer, Carcinoma, Non-small-cell Lung, Prostate Cancer
- Trial name
- NCT00132522
- Testing
- EMD 273066
- Where
- 5 sites in United States, Switzerland
- Volunteers
- 45 people
- Sponsor
- EMD Serono
Lung Cancer
Osimertinib Plus Chemotherapy in Uncommon EGFRm NSCLC
This is an open-label, single-arm, multicenter, exploratory Phase II study sponsored by Astrazeneca Investment (China) Co., LTD.
- Trial name
- MINOVA (NCT05215951)
- Testing
- osimertinib
- Where
- 6 sites in China
- Volunteers
- 4 people
- Sponsor
- AstraZeneca
NSCLC, Neoadjuvant Therapy
Serplulimab Combined With Chemotherapy in Patients With Resectable Non-small-cell Lung Cancer
China with high incidence of non-small cell lung cancer. In the past few decades, surgery, radiotherapy, chemotherapy and other treatments were continuously improved, however, the mortality of lung cancer patients was not…
- Trial name
- NCT05882513
- Testing
- Serplulimab and neoadjuvant therapy, surgical resection of lung cancer, Tumour will be Collected from participant. Fate of sample is Destruction after use
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Lung Cancer
Gemcitabine and Carboplatin Followed by Paclitaxel in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as gemcitabine, carboplatin, and paclitaxel work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00276588
- Testing
- carboplatin, gemcitabine hydrochloride, paclitaxel
- Where
- 2 sites in United States
- Volunteers
- 46 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Non-Small Cell Carcinoma of Lung, TNM Stage 4, Radiation Therapy
Radiotherapy to the Primary in Metastatic Non-small Cell Lung Cancer Patients
study the effect of radiotherapy to the primary lesion after first line systemic therapy in metastatic non-small cell lung cancer patients.
- Trial name
- NCT04776083
- Testing
- first line systemic therapy, 3D radiotherapy or IMRT
- Where
- Egypt
- Volunteers
- 75 people
- Sponsor
- Menoufia University
Phase 1 Portion : Non Small Cell Lung Cancer(NSCLC), Small Cell Lung Cancer(SCLC), Mesothelioma, Phase 2 Portion : Small Cell Lung Cancer(SCLC)
Two-Part, Open-Label, Multi-Center, Phase 1/2 Study of BIW-8962 as Monotherapy in Subjects With Lung Cancer
This Phase 1/2 study is designed to assess the following: safety and tolerability of BIW-8962, Dose Limiting Toxicities (DLTs), Maximum Tolerated Dose (MTD), Recommended Phase 2 Dose (RP2D) in Phase 1 in subjects with…
- Trial name
- NCT01898156
- Testing
- BIW-8962
- Where
- South Korea
- Volunteers
- 37 people
- Sponsor
- Kyowa Kirin Korea Co., Ltd.
Carcinoma, Non-Small-Cell Lung, Epidermal Growth Factor Receptor
Intrathecal Pemetrexed for Leptomeningeal Metastasis in EGFR-Mutant NSCLC
Leptomeningeal metastasis (LM) is a complication of advanced non-small cell lung cancer (NSCLC). The incidence of LM in NSCLC patients is around 3-5 %, reaching 9.4 % of those with an epidermal growth factor receptor (EGFR)…
- Conditions
- Carcinoma, Non-Small-Cell Lung, Epidermal Growth Factor Receptor, Leptomeningeal Metastasis
- Trial name
- NCT05805631
- Testing
- Pemetrexed
- Where
- Taiwan
- Volunteers
- 23 people
- Sponsor
- Taipei Veterans General Hospital, Taiwan
Breast Cancer, Lung Cancer
Zoledronate, Vitamin D, and Calcium With or Without Strontium 89 or Samarium 153 in Preventing or Delaying Bone Problems in Patients With Bone Metastases From Prostate Cancer, Lung Cancer, or Breast Cancer
RATIONALE: Zoledronate, vitamin D and calcium may prevent or delay bone pain and other symptoms caused by bone metastases. It is not yet known whether giving zoledronate together with vitamin D and calcium is more effective with…
- Conditions
- Breast Cancer, Lung Cancer, Metastatic Cancer, Pain
- Trial name
- NCT00365105
- Testing
- Calcium, Vitamin D, zoledronic acid
- Where
- 147 sites in United States
- Volunteers
- 261 people
- Sponsor
- Radiation Therapy Oncology Group
Non-small Cell Lung Cancer
Study to Assess the Efficacy and Safety of Adjuvant Osimertinib in NSCLC With Uncommon EGFRm
This is an open-label, multi-centre, single-arm study assessing the efficacy and safety of osimertinib as adjuvant treatment in stage IB-IIIB (8th AJCC) NSCLC with uncommon EGFRm after receiving complete surgical resection with…
- Trial name
- NCT05546866
- Testing
- Osimertinib
- Where
- 10 sites in China
- Volunteers
- 51 people
- Sponsor
- AstraZeneca
Non-small Cell Lung Cancer, Thoracic Surgery
Robotic Lobectomy vs. Thoracoscopic Lobectomy for Early Stage Lung Cancer: RCT
During video-assisted thoracoscopic lobectomy (VATS), the surgeon inserts a small camera attached to a thoracoscope that puts the image onto a video screen.
- Trial name
- NCT02617186
- Testing
- Video-assisted thoracoscopic surgery, Robotic thoracic surgery
- Where
- Canada
- Volunteers
- 446 people
- Sponsor
- St. Joseph's Healthcare Hamilton
Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma
Sapanisertib and Nivolumab for the Treatment of Stage I-IV Non-small Cell Lung Cancer in Patients Who Have Progressed on Prior PD-1/PD-L1 Inhibitor Therapy, I-OVERCOME Study
This phase I/II trial studies the side effects of sapanisertib and nivolumab and to see how well they work in treating patients with stage I-IV non-small cell lung cancer whose disease got worse on previous PD-1/PD-L1 inhibitor…
- Conditions
- Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage I Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8
- Trial name
- NCT05022394
- Testing
- Nivolumab, Sapanisertib
- Sponsor
- M.D. Anderson Cancer Center
Lung Cancer
Stereotactic Radiosurgery in Treating Patients Undergoing Chemotherapy and Radiation Therapy For Stage III Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as docetaxel and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00945451
- Testing
- CK
- Where
- France
- Volunteers
- 35 people
- Sponsor
- Centre Antoine Lacassagne
Carcinoma, Non-Small Cell Lung, Carcinoma, Small Cell Lung
Metabolomic Analysis of Lung Cancer
The purpose of this study is to learn more about the metabolic properties of lung cancer cells.
- Trial name
- NCT00263731
- Testing
- 13-C-glucose
- Where
- United States
- Volunteers
- 249 people, healthy volunteers welcome
- Sponsor
- University of Louisville
Lung Cancer
3-Dimensional Conformal Radiation Therapy Versus Intensity Modulated Radiation Therapy
Primary Objective: Developing Common Toxicity Criteria (CTC) 3.0 grade > 3 treatment related pneumonitis (TRP) or Developing local-regional recurrence among patients treated with 3D conformal radiation therapy (CRT) (Arm 1) or…
- Trial name
- NCT00520702
- Testing
- Intensity Modulated Radiation Therapy, 3-Dimensional Conformal Radiation Therapy
- Where
- United States
- Volunteers
- 168 people
- Sponsor
- M.D. Anderson Cancer Center
Carcinoma, Non-Small-Cell Lung, ALK Gene Mutation
French National Observatory of the Patients With Non-small Cell Lung (NSCLC) and Molecular Testings
The French National Cancer Institute (INCa) support a 28 hospital platforms network for molecular testing of cancer patients. These platforms routinely assess a panel of biomarkers in order to speed up access of French cancer…
- Conditions
- Carcinoma, Non-Small-Cell Lung, ALK Gene Mutation, KRAS Gene Mutation, BRAF Gene Mutation
- Trial name
- NCT01700582
- Where
- 133 sites in France
- Volunteers
- 17,664 people
- Sponsor
- Intergroupe Francophone de Cancerologie Thoracique
Non Small Cell Lung Cancer, Bone Metastases
Efficacy and Safety Study of ZOMETA® in Treatment of High-level NTX Non Small Cell Lung Cancer With Bone Metastasis
A multicenter prospective study to assess the efficacy and safety of ZOMETA® in treatment of high-level NTX non small cell lung cancer with bone metastasis.
- Conditions
- Non Small Cell Lung Cancer, Bone Metastases, High NTX Level
- Trial name
- NCT00762346
- Testing
- zometa
- Where
- China
- Volunteers
- 156 people
- Sponsor
- Sun Yat-sen University
Melanoma, Urothelial Carcinoma
A RC198 Study in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors
Safety study of RC198 in Subjects with Solid Tumors.
- Conditions
- Melanoma, Urothelial Carcinoma, Renal Cell Carcinoma, Non-small Cell Lung Cancer
- Trial name
- NCT05867303
- Testing
- RC198 Injection
- Where
- 5 sites in Australia, China
- Volunteers
- 48 people
- Sponsor
- RemeGen Co., Ltd.
NSCLC Stage IV, Oligometastasis
Toripalimab in Combination With Platinum-based Chemotherapy for Mutation-negative Stage IV Oligometastatic NSCLC
In recent years, immune checkpoint inhibitors targeting cytotoxic T-lymphocyte antigen-4, programmed death-1, and programmed death-ligand 1 have achieved milestones in the treatment of NSCLC, from back-line to first-line, and…
- Trial name
- NCT05055583
- Testing
- Toripalimab in Combination With Platinum-based Chemotherapy, Surgical treatment stage, Adjuvant treatment stage
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Tang-Du Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.